Nab paclitaxel in Bladder Cancer

Slides:



Advertisements
Similar presentations
Oncologic Drugs Advisory Committee
Advertisements

1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
Targeting Tumors Using Endogenous Albumin
Presented by Martin H. Cohen, M.D. at the 27 July 2004 meeting of the Oncologic Drugs Advisory Committee.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
Palumbo A et al. Proc ASH 2014;Abstract 175.
Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.
Xeloda ® monotherapy in pancreatic cancer: phase II study  42 patients with advanced/metastatic pancreatic cancer received intermittent Xeloda 1,250mg/m.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )
Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.
Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study Atul Sharma, Amit Dutt Dwary, Bidhu.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.
ESMO 2016 Nivolumab Data Study Ph Indication Line N Arms 1o EP ORR mDR
KEYNOTE-045: Updated Survival Analysis of Phase III Trial of Pembrolizumab vs Paclitaxel, Docetaxel, or Vinflunine in Pts With Advanced Urothelial Carcinoma.
Randomized Phase III Study Of Gemcitabine
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
A cura di Filippo de Marinis
Alessandra Gennari, MD PhD
Management of metastatic and recurrent head and neck cancer
BIBF 1120 (Nintedanib) in platinum-resistant ovarian cancer:
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
Phase II Study of Docetaxel (D) and Oxaliplatin (O) in Recurrent Metastatic Transitional Cell Carcinoma of the Bladder Davar D1, Appleman LA1, Friedland.
Fondazione IRCCS Istituto Nazionale Tumori
PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.
Farletuzumab in platinum sensitive ovarian cancer with low CA125
Gajria D et al. Proc SABCS 2010;Abstract P
University of Southern California, Norris Comprehensive Cancer Center
SARC003 Phase II Study of Gemcitabine & Docetaxel in Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable/Locally Recurrent Chondrosarcoma Elizabeth.
Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
Oki Y et al. Proc ASH 2013;Abstract 252.
Vahdat L et al. Proc SABCS 2012;Abstract P
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
Abraxane-Pembro nei carcinomi uroteliali avanzati
Goede V et al. Proc ASH 2014;Abstract 3327.
Abstract #LBA7511 Results of a Randomized, Phase III Trial of nab-Paclitaxel and Carboplatin Compared With Cremophor-based Paclitaxel and Carboplatin as.
Intervista a Lucio Crinò
Information for participating Sites
Ospedale Misericordia, Grosseto
Krop I et al. SABCS 2009;Abstract 5090.
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
CTCL: INNOVATIVE TREATMENTS GEMCITABINE
Nab-paclitaxel in Ovarian Cancer
ACT II: The Second UK Phase III Anal Cancer Trial
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
Presentation transcript:

Nab paclitaxel in Bladder Cancer

Summary of select novel intravesical agents Urologic Oncology: Seminars and Original Investigations 28 (2010) 108–111

Up to 50% of patients treated with intravesical agents for high grade nonmuscle invasive bladder cancer will have disease recurrence. Response rates to current second line intravesical therapies are low and for these high risk patients novel agents are necessary. Our previously completed phase I trial showed docetaxel was a safe agent for intravesical use. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007) has been shown to have increased solubility and lower toxicity compared to docetaxel in systemic therapy. Thus, we assessed the dose limiting toxicity and maximum deliverable dose of intravesical nanoparticle albumin-bound paclitaxel. J Urol, 2011

Study Design (1) For this phase I trial a modified Fibonacci dose escalation scheme was used with an initial dose of 150 mg in 30 ml NS given to the first 3 patients. If DLT (defined by the National Cancer Institute Common Toxicity Criteria version 3.0) did not develop in any patients the dose was increased by 75 mg for the subsequent 3 patients. J Urol, 2011

Study Design (2) Three patients were to be treated at each of 6 dose levels (150, 225, 300, 375, 450 and 500 mg) for a target enrollment of 18 patients. The nab-paclitaxel dose of 500 mg diluted in 100 ml NS was chosen as the target dose level because of the expected inability of patients to tolerate intravesical instillation volumes greater than 100 ml for the full 2-hour dwell time, and nab-paclitaxel has only been previously studied in a reconstituted suspension of 5 mg/ml. Therefore, 500 mg was deemed the MDD. The end point in phase I was when the maximum tolerated dose was achieved, defined as the dose at which DLT occurred or when a MDD was reached in the dose escalation scheme described without any DLT. J Urol, 2011

Patient Characteristics All patients had recurrent nonmuscle invasive transitional cell carcinoma, including 9 with stage Tis, 3 with high grade Ta and 6 with high grade T1 disease. J Urol, 2011

Results A total of 18 patients were enrolled in the study. One patient demonstrated measurable systemic absorption after 1 infusion. Grade 1 local toxicities were experienced by 10 (56%) patients with dysuria being the most common, and no grade 2, 3 or 4 drug related local toxicities were encountered. Of the 18 patients 5 (28%) had no evidence of disease at post-treatment evaluation. J Urol, 2011

Conclusions Intravesical nanoparticle albumin-bound paclitaxel exhibited minimal toxicity and systemic absorption in the first human intravesical phase I trial to our knowledge. A larger phase II study has begun to formally evaluate the activity of this regimen. J Urol, 2011

A phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladder. Neoadjuvant cisplatin-based chemotherapy benefits patients with bladder cancer, particularly in the 30% with pathologic complete response (pCR) at cystectomy. Many patients with bladder cancer are not candidates for cisplatin. Taxane-based regimens have activity in urothelial cancer. ABI-007 is an albumin-bound paclitaxel with increased activity and decreased toxicity compared to standard paclitaxel preparations. Smith, 2011

Methods Eligible pts have T2-4,N0,M0 or T any, N1- 3, M0 bladder cancer with ECOG PS 0-1, and adequate marrow (granulocyte count > 1,500/mm3, platelet > 100,000/mm3, and hemoglobin > 9.0 g/dl), hepatic (transaminases < 2.5 X upper limit of normal, alkaline phosphatase < 2.5 X upper limit of normal, and bilirubin < 1.5 mg/dl) and renal function (serum creatinine < 2.0 mg/dl and/or creatinine clearance > 40 ml/min). Treatment intravenous ABI-007 260 mg/m2 and carboplatin (target area under the curve=5) on day 1 with gemcitabine 800 mg/m2 on days 1 and 8, followed by radical cystectomy after three cycles of therapy. The primary study endpoint is the proportion of patients with pCR at cystectomy. Smith, 2011

Results 27 patients have been enrolled By clinical staging, 20 had T2 disease, 5 had T3, 2 had T4, and 2 had nodal enlargement. All are evaluable for toxicity with 22 evaluable for response (exclusions-3 for change in dose schedule, 1 each for refusal of cystectomy and withdrawal from study). 25/27 patients received all three cycles (78 total cycles) with doses reduced in 26 cycles for toxicity. Smith, 2011

Toxicities All patients had transient grade 3-4 neutropenia and 17 received filgrastim, but only two had febrile neutropenia. Six pts had pCR with an additional 5 having residual carcinoma in situ (CIS) and 1 with T1 disease at cystectomy. 54% of evaluable patients had no muscle invasive disease at cystectomy. Smith, 2011

Conclusions Neoadjuvant ACG is active in bladder cancer with pCR rate nearing 30% and nearly as many patients with CIS but no residual invasive disease. Marrow toxicity is significant but manageable. Smith, 2011

Phase II Study of Nab paclitaxel as 2nd Therapy in Patients with Metastatic Urothelial Carcinoma Study Design Open-label, single arm, multi-institutional phase II study Two-step enrollment design: Stage 1: If > 1/21 respond then proceed to Stage 2: Accrue 20 additional patients – If the total number of responses is  4  the drug is not effective Assuming 10-15% drop out rate, sample size = 48 total patients 90% power to detect a RR>20% Sridhar, 2011

Study Objectives Primary: to determine the overall response rate using RECIST Secondary: Time to disease progression Safety Overall survival Sridhar, 2011

Main Incl. & Excl. Eligibility Criteria TCC of the urothelium (including renal pelvis, ureter and bladder) Mixed histology (with squamous or adeno) allowed if TCC >50% of specimen Only one prior chemo regimen with platinum (≥ 1 cycle) for metastatic/recurrent disease Neoadjuvant/adjuvant chemo will be considered to be first line if progression < 12mths from last dose Age ≥18 years of age, ECOG PS ≤ 2, Hgb >90, and Adequate end organ function Prior taxane for metastatic disease (or ≤ 12mths since taxane containing neoadjuvant/adjuvant therapy) Pre-existing neuropathy ≥ grade 1 Uncontrolled brain metastasis (treated, stable disease is acceptable) Other investigational or XRT within 30 days before registration Sridhar, 2011 16

Statistical Hypothesis Two-stage design to test the null hypothesis P<=0.05 vs alternate P>=0.20 Stage 1: Enroll 21 pts. If > 2 responses proceed Stage 2: Accrue to total of 48 evaluable pts Design has a 90% power to detect a true RR of 20% or greater assuming a 15% drop out rate Sridhar, 2011

Nab paclitaxel dose (m2) Treatment Nab paclitaxel 260 mg/m2 IV over 30 minutes every 21 days Premedication not require but permitted 2 dose reductions permitted Standard anti-emetics as per institution for Nab paclitaxel Grade 2 neurotoxicity should lead to holding dose until ≤ grade 1 then one dose reduction Growth factor support permitted Dose Level Nab paclitaxel dose (m2) 260 -1 200 -2 160 Sridhar, 2011 18

Baseline Characteristics Number of patients 48* Age (years): mean (range) 68 (39-88) Gender: M / F 40 / 8 ECOG PS: 0 / 1 / 2 15 / 24 / 8 Histology TCC = 43; Mixed = 2; Missing = 3 Median time from last chemotherapy 5.2 mo (range 0.69-49 months) Prior platinum response Yes 53% No 47% * 1 patient inevaluable and 2 patients received only 1 treatment cycle Sridhar, 2011

Treatment Exposure & Dose Reductions Median number of cycles administered (range) 5.5 (1 – 15) Patients with at least one dose reduction* 17 / 48 (35%) * Most commonly due to fatigue or neuropathy Sridhar, 2011

Response Objective Response N=40* Number (%) Complete Response 1 (2.5%) Partial Response 11 (28%) Stable Disease 9 (23%) PD 20 (49%) *One patient was inevaluable for response, 7 patients are too early for evaluation. Sridhar, 2011 21

Toxicities – Grade 3 & 4 Toxicity % N=48 Grade 3&4 Pain Fatigue 45% Fatigue 8% Weakness 4% Neuropathy Joint stiffness 5% Hypertension 14% No grade 3/4 neutropenia and no febrile neutropenia Sridhar, 2011 23

Conclusions Single-agent ABI-007 was well tolerated with a Response Rate (CR+PR) of 33% (12/36) and a Clinical Benefit Rate (CR+PR+SD) of 58% (21/36), representing one of the highest reported response rates to date in the second-line UC setting. These results suggest further study of ABI-007 in urothelial carcinoma is warranted. Sridhar, 2011

Single Agent 2nd Line Trials Regimen Phase N Response Rate TTP Months Median Survival Lorusso 1998 Gemcitabine II 35 23% 3.8 5 Albers 2002 30 11% 4.9 8.7 Vaughn 2002 Paclitaxel 31 10% 2.2 7.2 Pronzato 1997 Ifosfamide 20 5% NR Witte 1997 56 20% 2.5 5.5 McCaffrey 1997 Docetaxel 13% 9 Sweeney 2006 Pemetrexed 47 28% 2.9 9.6 Dreicer 2007 Epothilone B 45 12% 2.7* 8 Bellmunt 2009 Vinflunine III 370 9% 3.0* 6.9 Sridhar 2011 Nab paclitaxel 33% 6.0* 10.8 *PFS

Combination 2nd Line Trials Regimen N RR Median Survival Krege 2001 Docetaxel/Ifosfamide 22 25% 4 Lin 2007 Gemcitabine/Ifosfamide 23 22% 4.8 Bellmunt 2002 MTX/Paclitaxel 20 32% 5 Sternberg 2001 Gemcitabine/Paclitaxel 41 60% 14.4 Fechner 2006 27 44% 13 Vaishampayan 2005 Paclitaxel/Carboplatin 44 16% 6 Pagliaro 2002 Ifosfamide/Gem/Cisplatin 49 41% NR Chen 2004 Gem/Docetaxel/Carboplatin 45% Tu 1995 Paclitaxel/Cisplatin/MTX 25 40% Sridhar 2011 nab-Paclitaxel 47 33% 10.8